Global Intravenous Immunoglobulin Market: Analyst’s Estimations

Since the first formulation of intravenous immunoglobulin (IVIG) that gained FDA approval back in 1980s, the concept has been harnessed relentlessly in the last three decades and adverse effects have been neutralized to a large extent. In the recent past, IVIG have proven their worth in treating autoimmune diseases such as primary humoral immunodeficiency (PIDD), multiple sclerosis, immune thrombocytopenia purpura (ITP), autoimmune haemolytic anemia, and Kawasaki syndrome. Going forward, intravenous immunoglobulin are expected to remain a viable alternative to other medications such as corticosteroids and immunosuppressants.  

According to the findings of this business intelligence report that has evaluated and estimated the commerce of the global IVIG market – the demand will expand at a formidable CAGR of 8.52% during the forecast period of 2017 to 2024. The analyst of the report has projected that the intravenous immunoglobulin market will have opportunities worth US$14,923.2 million by 2024 across the globe, which is substantially higher than the market’s calculated valuation of US$8,419.7 million as of 2017.

global intravenous immunoglobulin market

Apart from the prevalence of autoimmune disorders, the intravenous immunoglobulin market is foreseen to gain traction from factors such as increase in geriatric population, growing usage of off-label indications, advancements in the production technologies and purification methods, favorable government initiatives, and improvements in healthcare infrastructure across emerging economies. On the other hand, the report highlights high cost of treatment, long-term side-effects, stringent regulatory framework, and emergence of alternative therapies such as subcutaneous infusion IG (SCIG) and recombinant products are a few restraints obstructing the IVIG market from attaining its true potential.

CIDP to Remain Key Indication Segment Until 2024

On the basis of indication, this report segments the IVIG market into chronic inflammatory demyelinating polyneuropathy (CIDP), idiopathic thrombocytopenic purpura (ITP), primary humoral immunodeficiency, myasthenia gravis, hypogammaglobulinemia, guillain-barre syndrome, Kawasaki disease, multifocal motor neuropathy (MMN), and chronic lymphocytic leukemia. Among these, CIDP and primary humoral immunodeficiency are the two segments that constituted for more than half of the total demand in this market. While the former segment is gaining traction from the rising prevalence of the diseases, the latter segment is driven by it being an on-label indication for IVIG. By 2024, the two segments are estimated to generate a revenue of US$4,989.4 million and US$4,145.4 million respectively.

The report also bifurcates the intravenous immunoglobulin market based on end users, into hospitals, clinics, and home care settings. Hospitals are expected to continue providing for the most prominent chunk of demand over the course of 2017 to 2024, although the other two are primed for stronger growth rates.

Asia Pacific Emerging As a Region of Substantial Potential

Geographically, the analyst of the report has evaluated the potential of demand for IVIG that can be expected out of the regions of Asia Pacific, Europe, North America, Latin America, and the Middle East and Africa. In 2017, the North America intravenous immunoglobulin market posed a valuation of US$3,814.8 million and is estimated to generate more than 43.3% of the total demand. Wide range of products available, advancements in technology, and increasing number of patients with blood and neurological disorders are the major drivers of the North America IVIG market. Although Europe is expected to hold onto its position as the second most profitable region in terms of demand, Asia Pacific is a region wherein the demand is poised to expand at most robust CAGR of 9.5% during 2017 to 2024. By the end of 2024, the Asia Pacific IVIG market is estimated to be worth US$2,826.1 million.

The analyst of the report has identified CSL Behring LLC, Grifols S.A., Octapharma AG, and Baxalta Incorporated as the prominent companies currently ahead of the curve in the global IVIG market. The report contains a featured section on the competitive landscape, profiling most of the leading players as well as a number of other promising participants.

Intravenous Immunoglobulin (IVIG) Market: Scope and Methodology

This report on the global intravenous immunoglobulin (IVIG) market analyzes the current and future prospects of the market. The report comprises an elaborate executive summary, including a market snapshot that provides overall information of various segments and sub-segments. The research is a combination of primary and secondary research. Primary research formed the bulk of our research efforts along with information collected from telephonic interviews and interactions via e-mails. Secondary research involved study of company websites, annual reports, press releases, stock analysis presentations, and various international and national databases. The report provides market size in terms of US$ Mn for each segment for the period from 2014 to 2024, considering the macro and micro environmental factors. Growth rates for each segment within the global intravenous immunoglobulin (IVIG) market have been determined after a thorough analysis of past trends, demographics, future trends, technological developments, and regulatory requirements. 

A detailed qualitative analysis of factors responsible for driving and restraining market growth and future opportunities has been provided in the market overview section. This section of the report also provide insights into the key trends of the intravenous immunoglobulin (IVIG) market such as shift from intravenous to subcutaneous infusion of immunoglobulin. The key market indicators influencing global intravenous immunoglobulin (IVIG) market taken into consideration include prevalence of immunological disorders, global blood and plasma yield and geriatric population. The report also includes market attractiveness analysis of the major segments that provides a thorough analysis of the overall competitive scenario in the global intravenous immunoglobulin (IVIG) market. The report also highlights key events of the global intravenous immunoglobulin industry. A value chain analysis along with list of major players, hospitals and distributors is also included in the report.

Market revenue in terms of US$ Mn for the period between 2014 and 2024 along with the compound annual growth rate (CAGR %) from 2017 to 2024 are provided for all the segments, considering 2016 as the base year. The year on year growth of global intravenous immunoglobulin (IVIG) market for each segment is also reflected. Additionally, market related factors such as increasing preference for product innovation, and growing number of acute and chronic patients in various geographies and historical year-on-year growth have been taken into consideration while estimating the market size.

Intravenous Immunoglobulin (IVIG) Market: Segmentation

Based on indication, the global intravenous immunoglobulin (IVIG) market has been segmented into chronic inflammatory demyelinating polyneuropathy (CIDP), primary humoral immunodeficiency, idiopathic thrombocytopenic purpura (ITP), Guillain-Barre syndrome, myasthenia gravis, multifocal motor neuropathy (MMN), Kawasaki disease, hypogammaglobulinemia, chronic lymphocytic leukemia, and others. Based on end-user, the market has been segmented into hospitals, clinics, and home care. Hospitals segment is expected to remain dominant during the forecast period. However, home care segment is expected to grow at a higher CAGR than others.

Geographically, the global intravenous immunoglobulin (IVIG) market has been segmented into five regions: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. In addition, the regions have been further segmented into major countries from each region. These include the U.S., Canada, the U.K., Germany, France, Italy, Spain, China, Australia, India, Japan, Brazil, and Mexico.

Intravenous Immunoglobulin (IVIG) Market: Competitive Landscape

The report also profiles major players in the intravenous immunoglobulin (IVIG) market based on various attributes such as company overview, financial overview, SWOT analysis, key business strategies, product portfolio, and recent developments. A thorough market share analysis of major companies operating in the intravenous immunoglobulin (IVIG) market is provided in the report. The report also includes a competition matrix that provides insights into recent developments and activities done by the major market players. Key companies profiled in the report include Baxalta Incorporated, Biotest AG, China Biologic Products, Inc., CSL Behring LLC, Grifols S.A., Kedrion S.p.A., LFB Biomedicaments S.A., Octapharma AG, and Sanquin Plasma Products B.V.

The global intravenous immunoglobulin (IVIG) market has been segmented as follows:

Global Intravenous immunoglobulin (IVIG) Market, by Indication

  • Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
  • Primary Humoral Immunodeficiency
  • Idiopathic Thrombocytopenic Purpura (ITP)
  • Guillain-Barre Syndrome
  • Myasthenia Gravis
  • Multifocal Motor Neuropathy (MMN)
  • Kawasaki Disease
  • Hypogammaglobulinemia
  • Chronic Lymphocytic Leukemia
  • Others

Global Intravenous immunoglobulin (IVIG) Market, by End-user

  • Hospitals
  • Clinics
  • Home Care

Global Intravenous immunoglobulin (IVIG) Market, by Geography

  • North America
    • U.S.
    • Canada
  • Europe
    • U.K.
    • Germany
    • France
    • Spain
    • Italy
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • Australia
    • India
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • Rest of Middle East & Africa